Dr. Lal PathLabs Ltd
LALPATHLABDr. Lal PathLabs Ltd
LALPATHLAB
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 63.07 | 13.43 | 0.59% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast from 20 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.
Investor Presentation
View olderPeers
Compare with peersMax Healthcare Institute Ltd
Apollo Hospitals Enterprise Ltd
Fortis Healthcare Ltd
Global Health Ltd
Narayana Hrudayalaya Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 811.09 | 939.92 | 1,088.14 | 1,249.37 | 1,385.41 | 1,632.60 | 2,139.96 | 2,058.60 | 2,295.81 | 2,425.60 | ||||||||||
Raw Materials | 172.92 | 197.08 | 226.03 | 262.35 | 298.70 | 397.26 | 502.25 | 447.15 | 451.42 | 1,688.60 | ||||||||||
| Power & Fuel Cost | 12.78 | 13.58 | 15.32 | 15.74 | 16.74 | 18.62 | 22.11 | 25.91 | 26.18 | |||||||||||
| Employee Cost | 136.83 | 152.01 | 180.75 | 208.29 | 242.64 | 273.70 | 364.94 | 376.52 | 424.57 | |||||||||||
| Selling & Administrative Expenses | 119.68 | 149.29 | 175.89 | 208.79 | 184.69 | 176.29 | 253.82 | 268.27 | 275.58 | |||||||||||
| Operating & Other expenses | 139.39 | 162.90 | 194.94 | 214.59 | 244.00 | 279.12 | 383.56 | 409.20 | 439.65 | |||||||||||
EBITDA | 229.49 | 265.06 | 295.21 | 339.61 | 398.64 | 487.61 | 613.28 | 531.55 | 678.41 | 737.00 | ||||||||||
| Depreciation/Amortization | 28.28 | 27.54 | 33.06 | 38.22 | 72.81 | 77.20 | 108.11 | 150.19 | 143.60 | 142.60 | ||||||||||
| PBIT | 201.21 | 237.52 | 262.15 | 301.39 | 325.83 | 410.41 | 505.17 | 381.36 | 534.81 | 594.40 | ||||||||||
| Interest & Other Items | 0.50 | 0.70 | 0.84 | 0.84 | 15.31 | 16.00 | 30.18 | 37.53 | 29.36 | 25.60 | ||||||||||
| PBT | 200.71 | 236.82 | 261.31 | 300.55 | 310.52 | 394.41 | 474.99 | 343.83 | 505.45 | 568.80 | ||||||||||
| Taxes & Other Items | 68.52 | 82.23 | 90.59 | 101.37 | 84.56 | 102.79 | 130.15 | 104.98 | 147.72 | 167.40 | ||||||||||
| Net Income | 132.19 | 154.59 | 170.72 | 199.18 | 225.96 | 291.62 | 344.84 | 238.85 | 357.73 | 401.40 | ||||||||||
| EPS | 19.25 | 18.65 | 20.52 | 23.90 | 27.11 | 34.99 | 41.38 | 28.65 | 42.88 | 48.08 | ||||||||||
| DPS | 2.45 | 3.00 | 4.50 | 6.00 | 12.00 | 20.00 | 12.00 | 6.00 | 18.00 | 24.00 | ||||||||||
| Payout ratio | 0.13 | 0.16 | 0.22 | 0.25 | 0.44 | 0.57 | 0.29 | 0.21 | 0.42 | 0.50 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dr. Lal PathLabs Ltd | 70.77 | 13.43 | 0.59% |
| Max Healthcare Institute Ltd | 109.68 | 13.80 | 0.13% |
| Apollo Hospitals Enterprise Ltd | 115.81 | 14.22 | 0.22% |
| Fortis Healthcare Ltd | 86.06 | 6.02 | 0.15% |
Price Comparison
Compare LALPATHLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.40%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Dr. Lal PathLabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.2006% | Percentage of the fund’s portfolio invested in the stock 0.84% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/61 (0) |
UTI Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4115% | Percentage of the fund’s portfolio invested in the stock 1.35% | Change in the portfolio weight of the stock over the last 3 months -0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/69 (-2) |
SBI Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7752% | Percentage of the fund’s portfolio invested in the stock 0.67% | Change in the portfolio weight of the stock over the last 3 months 0.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 73/85 (+5) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr. Lal PathLabs Ltd
Events
Dividend Trend
No Trend In Dividends
LALPATHLAB has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.59%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.94 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 5, 2024
Dividend/Share
₹6.00
Ex DateEx Date
Nov 5, 2024
Cash Dividend
Ex DateEx DateAug 20, 2024
Dividend/Share
₹6.00
Ex DateEx Date
Aug 20, 2024
Cash Dividend
Ex DateEx DateJun 10, 2024
Dividend/Share
₹6.00
Ex DateEx Date
Jun 10, 2024
Cash Dividend
Ex DateEx DateFeb 13, 2024
Dividend/Share
₹12.00
Ex DateEx Date
Feb 13, 2024
Cash Dividend
Ex DateEx DateAug 11, 2023
Dividend/Share
₹6.00
Ex DateEx Date
Aug 11, 2023
Dr Lal Pathlabs has allotted 5,483 equity shares under ESOP on 18 December 2024. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to Rs 83,58,77,350/- divided into 8,35,87,735 equity shares of Rs 10/-each. Powered by Capital Market - Live
Dr Lal Pathlabs has allotted 3,000 equity shares under ESOP on 05 December 2024. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to Rs 83,58,22,520/- divided into 8,35,82,252 equity shares of Rs 10/-each. Powered by Capital Market - Live
Dr. Lal PathLabs approved allotment of 5,000 Equity Shares under the ESOP 2010 Plan of the Company on 30th October 2024 through circular resolution.Powered by Capital Market - Live
Dr Lal Pathlabs has fixed 05 November 2024 as record date for 2nd interim dividend of Rs 6 per share for FY 2024-25. Powered by Capital Market - Live
Net profit of Dr Lal Pathlabs rose 18.21% to Rs 129.20 crore in the quarter ended September 2024 as against Rs 109.30 crore during the previous quarter ended September 2023. Sales rose 9.80% to Rs 660.20 crore in the quarter ended September 2024 as against Rs 601.30 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales660.20601.30 10 OPM %30.6729.57 - PBDT218.40188.10 16 PBT183.10152.20 20 NP129.20109.30 18 Powered by Capital Market - Live
Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
Dr Lal Pathlabs has allotted 93,900 equity shares under Dr. Lal PathLabs Employee Stock Option Plan, 2022. Pursuant to the above allotment, the paid-up equity share capital of the Company increased to Rs 83,57,42,520/- divided into 8,35,74,252 equity shares of Rs 10/- each.Powered by Capital Market - Live
Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 7 August 2024, inter alia, have recommended the interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Net profit of Dr Lal Pathlabs rose 28.81% to Rs 106.40 crore in the quarter ended June 2024 as against Rs 82.60 crore during the previous quarter ended June 2023. Sales rose 11.26% to Rs 601.90 crore in the quarter ended June 2024 as against Rs 541.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales601.90541.00 11 OPM %28.2427.02 - PBDT184.60152.60 21 PBT149.90117.50 28 NP106.4082.60 29 Powered by Capital Market - Live
Revenue from operations increased 11.26% YoY to Rs 601.9 crore during the quarter. Profit before tax (PBT) stood at Rs 149.9 crore, up 27.57% as comapred with Rs 117.5 crore posted in same quarter last year. Total expenses increased 7.92% to Rs 472.6 crore in Q1 FY25 as compared with Rs 437.9 crore posted in corresponding quarter last year. Cost of material consumed stood at Rs 119.4 crore (up 5.57% YoY), employee benefit expenses was at Rs 116.6 crore (up 11.37% YoY), fees to collection centers/ channel partners was at Rs 83.7 crore (up 12.35% YoY) during the period under review. During the quarter EBITDA jumped to Rs 170 crore as compared with Rs 146 crore posted in same quarter last year, registering the growth of 16.2%. Meanwhile, the company's board declared interim dividend of Rs 6 per share for FY25. Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.94%, vs industry avg of 10.02%
Increasing Market Share
Over the last 5 years, market share increased from 3.41% to 3.7%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 12.42%, vs industry avg of 42.9%